Top in endocrinology: PFAS linked to thyroid cancer; non-insulin agents in type 1 diabetes

Adults who were exposed to higher levels of endocrine-disrupting chemicals were more likely to be diagnosed with thyroid cancer, according to a study published in eBioMedicine.

In a nested case-control study, researchers investigated associations between thyroid cancer and exposure to five different types of PFAS. They found a 56% increased risk for thyroid cancer for each doubling of linear PFOS intensity. It was the top story in endocrinology last week.

Another top story featured a conversation between Susan Weiner, MS, RDN, CDCES, FADCES, and Joshua J. Neumiller, PharmD, CDCES, FADCES, FASCP, about how to safely use SGLT2 inhibitors and GLP-1 receptor agonists for type 1 diabetes treatment and prevention. Neumiller discussed the risk for diabetic ketoacidosis with SGLT2 inhibitors, as well as the risk for hypoglycemia when used in combination with insulin.

Read these and more top stories in endocrinology below:

PFAS endocrine-disrupting chemicals linked to higher odds of thyroid cancer

Exposure to a class of endocrine-disrupting chemicals may increase the risk for developing thyroid cancer, according to a study published in eBioMedicine. Read more.

What to know about using non-insulin agents in type 1 diabetes

Weiner talks with Neumiller about nuances of using SGLT2 inhibitors and GLP-1 receptor agonists in type 1 diabetes, and a therapy for delaying type 1 diabetes onset. Read more.

FDA grants breakthrough therapy designation for oral congenital adrenal hyperplasia drug

The FDA granted breakthrough therapy designation for an oral non-glucocorticoid medication for the treatment of congenital adrenal hyperplasia, according to an industry press release. Read more.

Voice-based AI app reduces time to optimal basal insulin dose in type 2 diabetes

Adults with type 2 diabetes who used an artificial intelligence-based app to manage their basal insulin reached their optimal dose in a shorter amount of time than adults receiving standard of care, according to a study data. Read more.

Metabolic syndrome linked to higher carotid artery thickness for women, regardless of BMI

Women with metabolic syndrome are more likely to have increased risk for atherosclerotic changes than women without metabolic syndrome, regardless of whether they also have obesity, according to study findings published in Menopause. Read more.